Bioxytran Updates on Pipeline Progress Across Antiviral and Oxygen Transport Programs

Bioxytran, Inc. provided a corporate update on January 29, 2026, summarizing prior program developments and reinforcing its strategic direction for 2026. The company reiterated its focus on advancing ProLectin-M, its lead antiviral candidate, under an active Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

ProLectin-M, a broad-spectrum antiviral program, has previously entered clinical trials. Bioxytran announced in October 2025 the completion of a randomized, double-blind, placebo-controlled clinical trial. Data from this trial are expected to inform Phase 3 study design and will be submitted to regulators. The company also completed dose optimization work in May 2025 intended to support additional clinical trial planning and agency submissions.

In parallel, Bioxytran continues to advance its oxygen transport platform, targeting stroke and neurodegenerative diseases. This includes development efforts on a universal oxygen carrier (UOC) and associated measurement and analytical approaches. In July 2024, Bioxytran announced a joint venture with the Heme Foundation to develop this oxygen carrier as an alternative to blood transfusions. The company is also exploring oncology applications through its galectin science, as detailed in a January 2025 preprint.

David Platt, Ph.D., CEO of Bioxytran, stated that the company enters 2026 with momentum across its platforms. He emphasized the team's focused execution on building data packages, advancing regulatory pathways, and expanding the scientific foundation to pursue clinical and strategic opportunities.